98%
921
2 minutes
20
Background: The adoption of direct oral anticoagulants (DOACs) has changed practice in prevention of stroke in atrial fibrillation (AF). We used Irish data national data on stroke and anticoagulation therapy over 9 years to investigate changes in anticoagulation practice and potential consequences on stroke prevalence and thrombolysis.
Methods: AF, anticoagulation, thrombolysis, and stroke data from the Irish National Audit of Stroke (INAS) 2013-2021 were reviewed. The proportion of patients with ischemic stroke (IS) and intracerebral hemorrhage (IH) with known AF admitted on anticoagulation was determined. Effects on age distribution in the population and thrombolysis practice were assessed.
Results: AF data were available on 34,630 of 35,241 individuals (98.3%) included in INAS; median age was 74 years and 56% were male. AF was found in 10,016 (28.9%, 9059 IS, 957 IH). 6313 had known AF prior to stroke (63.1%). The proportion all total IS due to AF decreased by 15.3% (31.3%-26.5%, chi-square = 24.6, p < 0.0001). The proportion of IH did not change significantly (21.6%-20.2%, chi-square = 1.8, p = 0.18). Over the 9 years, 3875 (38.6%) of the subjects with AF were recorded as receiving anticoagulants at admission. In 2013, 4.4% of AF-associated strokes were admitted on a DOAC and 21.4% on warfarin; by 2021, 44.1% were receiving a DOAC and 6.2% warfarin. There was a strong inverse correlation between the proportion of anticoagulated stroke patients and the total proportion of AF-associated strokes over time (r = -0.82, p = 0.006). In contrast, no correlation was found between increasing DOAC usage and IH (r = 0.14, p = 0.71). Increased anticoagulation usage correlated with a reduction in patients ⩾ 80 years (r = -0.83, p = 0.006) and also correlated with a relative reduction of 30.1% in subjects thrombolysed <4 h from onset (r = -0.89, p = 0.001).
Conclusion: DOACs have led to increased use of anticoagulation, but warfarin use fell by two-thirds. There has been a reduction in the proportion of AF-associated IS without a noticeable increase in IH. Increased anticoagulation correlated with reduced numbers of strokes in those >80 years and in the proportion of patients thrombolysed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/17474930231206680 | DOI Listing |
Eur J Contracept Reprod Health Care
September 2025
Federal University of Minas Gerais, Belo Horizonte, Brazil.
Objective: To systematically review the available evidence on changes in health-related quality of life (HRQoL) associated with the levonorgestrel-releasing intrauterine system (LNG-IUS) for contraception or menstrual bleeding management in women with a history of venous thromboembolism (VTE), regardless of anticoagulant use.
Methods: This systematic review was conducted following Cochrane Collaboration guidelines and the PRISMA statement. A comprehensive search was carried out in PubMed, Embase, Cochrane Central, Scopus, Web of Science, and the Virtual Health Library (VHL), without language or date restrictions.
J Clin Neurosci
September 2025
Departments of Neurosurgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Objectives: Traumatic brain injury (TBI) is a significant contributor to long-term disability and imposes substantial costs, which may include excess, duplicative, or unnecessary imaging, hospitalizations or transfers, and superfluous consultations. We examined the use of the Brain Injury Guidelines (BIG) in 144 consecutive patients presenting with TBI.
Methods: Patients with TBI evaluated consecutively between April 2024 and September 2024 were prospectively classified into BIG 1, 2, and 3 categories and retrospectively assessed.
Blood Transfus
August 2025
Anesthesia, Intensive Care and Perioperative Medicine, Nouvel Hôpital Civil, Strasbourg University Hospital, Strasbourg, France.
Background: Ensuring transfusion safety remains a major challenge. Pathogen-reduction technologies (PRT), such as the INTERCEPT™ Blood System (IBS), use amotosalen (a psoralen) as intercalating agent in nucleic acids and ultraviolet A (UV-A) light to block pathogen replication, reducing the risk of transfusion-transmitted infections. While IBS is approved for platelet concentrate (PC) treatment, its clinical impact on platelet function remains debated.
View Article and Find Full Text PDFAnn Med Surg (Lond)
September 2025
Sheikh Khalifa Medical City, Ajman, United Arab Emirates.
Introduction: The infection caused by the COVID-19 virus is associated with thromboembolic events and severe inflammatory reactions, significantly impacting the prognosis of infected patients. Numerous studies have indicated that COVID-19 patients often exhibit a hypercoagulable state, disseminated intravascular coagulation, and overwhelming inflammation, particularly in critically ill patients with multiple comorbidities requiring admission to the ICU. This study aims to assess the prognostic significance of alterations in coagulation, inflammatory, and blood chemistry markers in COVID-19 patients both before and during admission to the ICU.
View Article and Find Full Text PDFDrug Des Devel Ther
September 2025
Hebei General Hospital, Hebei Key Laboratory of Clinical Pharmacy, Shijiazhuang, 050051, People's Republic of China.
Background: Apixaban and rivaroxaban are oral direct factor Xa inhibitors, primarily eliminated through CYP3A4-mediated metabolism and direct intestinal excretion. Previous studies suggest that palbociclib, a CDK4/6 inhibitor, may increase the systemic exposure of these anticoagulants; however, the specific pharmacokinetic mechanisms remain unclear. This study aims to evaluate the effects of palbociclib on the pharmacokinetics of apixaban and rivaroxaban using a rat model to optimize combined drug regimens.
View Article and Find Full Text PDF